ATE405828T1 - Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik - Google Patents

Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik

Info

Publication number
ATE405828T1
ATE405828T1 AT06113906T AT06113906T ATE405828T1 AT E405828 T1 ATE405828 T1 AT E405828T1 AT 06113906 T AT06113906 T AT 06113906T AT 06113906 T AT06113906 T AT 06113906T AT E405828 T1 ATE405828 T1 AT E405828T1
Authority
AT
Austria
Prior art keywords
clinics
biomarkers
cdk inhibitors
response monitoring
mammal
Prior art date
Application number
AT06113906T
Other languages
English (en)
Inventor
Wanda Eve Depinto
Xuefeng Yin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE405828T1 publication Critical patent/ATE405828T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
AT06113906T 2005-05-25 2006-05-15 Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik ATE405828T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68450205P 2005-05-25 2005-05-25

Publications (1)

Publication Number Publication Date
ATE405828T1 true ATE405828T1 (de) 2008-09-15

Family

ID=36954240

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06113906T ATE405828T1 (de) 2005-05-25 2006-05-15 Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik

Country Status (9)

Country Link
US (1) US20060269482A1 (de)
EP (1) EP1726953B1 (de)
JP (1) JP2006325593A (de)
CN (1) CN101078716A (de)
AT (1) ATE405828T1 (de)
CA (1) CA2545426A1 (de)
DE (1) DE602006002311D1 (de)
ES (1) ES2313556T3 (de)
SG (1) SG127843A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114828B2 (en) 2007-04-16 2012-02-14 Honeywell International Inc. Azeotrope-like compositions of tetrafluoropropene and alcohols
WO2013071415A1 (en) * 2011-11-15 2013-05-23 University Health Network Targeting the rb pathway for the prevention of cancer
CN116240261B (zh) * 2023-02-22 2024-05-14 迈杰转化医学研究(苏州)有限公司 一种检测pbmc中shp2抑制剂活性的试剂盒及其方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1207395A4 (de) * 1999-08-04 2003-08-13 Med & Biological Lab Co Ltd Verfahren zum messen der kinaseaktivität eines cyclin/cdk-komplexes
US20030166016A1 (en) * 2000-04-28 2003-09-04 Foster Barbara A. Assay methods for cyclin dependent kinases
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives

Also Published As

Publication number Publication date
EP1726953B1 (de) 2008-08-20
DE602006002311D1 (de) 2008-10-02
JP2006325593A (ja) 2006-12-07
SG127843A1 (en) 2006-12-29
CA2545426A1 (en) 2006-11-25
CN101078716A (zh) 2007-11-28
US20060269482A1 (en) 2006-11-30
ES2313556T3 (es) 2009-03-01
EP1726953A1 (de) 2006-11-29

Similar Documents

Publication Publication Date Title
ATE490306T1 (de) Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
ATE488765T1 (de) Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung
ATE531820T1 (de) Gesundheitszustandstest
DK2360475T3 (da) Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
ATE537450T1 (de) Igfbp2-biomarker
WO2008041953A3 (en) Dengue diagnosis and treatment
ATE440151T1 (de) Verfahren zur beurteilung eines krankheitzustandes mittels nachweis von partikel- und nicht partikelgebundenen nukleinsäuren in blutplasma und -serum
JP2008514209A5 (de)
BRPI0715126B8 (pt) métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
NO20055025L (no) Multiplex screening for lysosomale lagringsforstyrrelser (LSD)
DE602005019694D1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
DE602006017058D1 (de) Verfahren zur stratifizierung von herzinsuffizienz
WO2010054195A3 (en) Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
ATE405828T1 (de) Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE543914T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
ATE449380T1 (de) System und verfahren zur quantitativen anwendungsmessung
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
WO2010045224A3 (en) Methods for the selection of therapeutic treatments for cancer
WO2007127002A3 (en) Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties